US drug major Bristol-Myers Squibb (NYSE: BMY) has reported second-quarter 2014 results, which show a 4% decline on total revenues to $3.9 billion over the same period last year.
Despite being down on second quarter figures for 2013, Reuters reported that the revenues were better than expected, topping Wall Street expectations of $3.85 billion. Bristol-Myers Squibb accounts for this by saying sales would have risen 7% had it not sold its global diabetes business to AstraZeneca. The figures being better than expected can be attributed by cost controls and good performance by its newer drugs.
The company earned $333 million, which equates to $0.20 per share, and compares poorly with $536 million and $0.32 per share in the same period for the previous year. Non-generally accepted accounting principles (GAAP) diluted EPS was $0.48.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze